Show simple item record

dc.contributor.authorNuthalapati, S.
dc.contributor.authorHoles, L.
dc.contributor.authorPrchal, J.
dc.contributor.authorHarrison, C.
dc.contributor.authorSomervaille, Tim C P
dc.contributor.authorHayslip, J.
dc.contributor.authorPotluri, J.
dc.contributor.authorMenon, R.
dc.contributor.authorMensing, S.
dc.date.accessioned2021-04-20T08:08:22Z
dc.date.available2021-04-20T08:08:22Z
dc.date.issued2021en
dc.identifier.citationNuthalapati S, Holes L, Prchal J, Harrison C, Somervaille TCP, Hayslip J, et al. PK/PD model prediction of platelet reduction to guide phase III dose selection for navitoclax added on to ruxolitinib in myelofibrosis. Clinical Pharmacology & Therapeutics. 2021;109.en
dc.identifier.urihttp://hdl.handle.net/10541/623946
dc.description.abstractNoneen
dc.language.isoenen
dc.titlePK/PD model prediction of platelet reduction to guide phase III dose selection for navitoclax added on to ruxolitinib in myelofibrosisen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentClinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, USA;en
dc.identifier.journalClinical Pharmacology & Therapeuticsen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record